A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

NCT01363713 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2014-10-06

Study results available
· View outcomes & findings →

Summary

Safety and efficacy of DE-114 ophthalmic solution will be evaluated in patients with allergic conjunctivitis, in an open-label, multicenter study.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

DE-114 ophthalmic solution

Sponsors & Collaborators

  • Santen Pharmaceutical Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2012-09-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01363713 on ClinicalTrials.gov